To study the efficacy of CCSC-derived DRibbles as potent tumor antigens, CD44, a robust cell surface marker of CCSCs, was used to enrich CCSCs from murine CT-26 colon cancer cell line. The gene discussed is CD44; the disease is malignant colon neoplasm.